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Abstract The Subcutaneous Internal Cardiac Defibrillator
(S-ICD) represents a major advance in the care of patients
who have an indication for an internal cardiac defibrillator
without pacing indications. Its main advantage is that it can
deliver a shock to cardiovert ventricular arrhythmias utilising
a tunnelled subcutaneous lead, negating the risks associated
with conventional transvenous systems. Initial studies have
shown comparable efficacy in cardioversion of induced and
spontaneous ventricular tachycardia (VT) and ventricular fi-
brillation (VF) when compared to conventional transvenous
systems. In addition, inappropriate shocks occurred in a sim-
ilar percentage of patients to conventional ICD studies. Com-
plication rates are low and relate largely to localised wound
infections, treated successfully with antibiotics. The long term
efficacy of the device is yet to be ascertained, however, a
randomised trial & prospective registries are currently in
progress to enable direct comparison with transvenous ICDs.
This article summarises the early clinical experience and trials
in the implantation of the S-ICD.
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Introduction
The Subcutaneous Internal Cardiac Defibrillator (S-ICD) rep-
resents a significant technological advance in the prevention
of sudden cardiac death avoiding the need for an intravascular
lead in ICD recipients without pacing indications [1–3].This is
a particular advantage in young patients who can then avoid
chronic lead complications of fracture & insulation breaks,
patients with vascular access issues (paediatric, congenital
heart disease, venous occlusion) or high risk of bacteraemias,
e.g. renal dialysis & chronic indwelling catheters. Following
initial approval in Europe in 2009 and the FDA IDE study in
2012 [4••], this technology is being employed clinically
worldwide. Initial small single centre experience is being built
upon with ongoing data collection from IDE study patients
and the EFFORTLESS (Evaluation oF FactORs ImpacTing
CLinical Outcome and Cost EffectiveneSS) S-ICDRegistry in
Europe [4••, 5••, 6••]. The latter is the first ICD device study to
collect detailed implant and follow-up data in 1000 patients up
to 5 years post procedure providing real world experience
outside the usual remit of randomised controlled trials. In this
review, the current evidence relating to S-ICD system perfor-
mance & outcomes plus issues of optimal patient selection
will be discussed.
Overview
The details of the S-ICD system and implantation technique
have been described elsewhere [2, 7•]. In summary, the device
is placed in the left lateral position via a lateral submammary
incision and the lead tunnelled to be positioned parasternally
sensing the surface ECG electrogram in three vectors (Fig. 1).
Advances in sensing algorithm technology and programming
have facilitated optimisation of surface ECG sensing to min-
imise inappropriate shocks for sinus tachycardia and rapidly
conducted atrial fibrillation (AF). These advances have main-
ly arisen through software developments in signal processing
and optimisation of programming [8]. The device has two
programmable zones of tachycardia detection, a supraventric-
ular tachycardia (SVT) discrimination zone and a ventricular
fibrillation (VF) zone. The latter is purely dictated by ventric-
ular rate whilst the SVT discrimination zone utilises a number
of parameters including electrogram morphology and stability
to differentiate between ventricular tachycardia (VT)/VF and
SVT. Therapy is then withheld if SVT discrimination criteria
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are met below the VF therapy heart rate threshold. These
algorithms can be ineffective if the patient develops bundle
branch block during SVT, although this can be overcome by
employing an electrogram template recording aberrant beat
morphology if it has been recognised as an issue during
screening. However, major challenges remain with T wave
oversensing and rapidly conducted AF into the VF zone when
only a rate criterion is applied. T wave oversensing can be
minimised by optimising the sensing vector prior to
implant and performing an exercise test examining this
vector(s) to determine whether this will be an issue
risking inappropriate shocks [8, 9] (Fig. 1). A recent
paper from the Dutch group evaluated the factors most
likely to cause a failure in ECG screening for the S-ICD
[10•]. They examined patients who did not have pacing
indications and accepted only those patients that had at
least one suitable sensing vector for distinguishing QRS
complexes and T waves. On this basis, they found
7.4 % of cases (all male) did not have suitable sensing
vectors in the lying and standing position, the main
factors responsible for ECG screening failure being hy-
pertrophic cardiomyopathy, increased BMI, a broad
QRS, and an R:T ratio of <3 in the ECG lead with
the largest Twave. This screening failure rate is relatively low,
but it may be possible to address this with more tailored
algorithms in the future or by using more bespoke specific
separate sensing electrode placements to minimise this prob-
lem in certain cases. These electrodes could be separate from
the shocking coils, although it is already being recognised that
in more centrally positioned hearts one can place the ICD
electrode in the right parasternal position as opposed to the
left, achieving optimal sensing and effective cardioversion of
induced VF if necessary.
Efficacy in the Cardioversion of VF
The critical concerns of the S-ICD from both a clinical
and regulatory perspective have been both the prompt
detection and conversion of VF. This has been carefully
addressed both in initial phase 1 studies of the system
and formally in the IDE trial as well as EFFORTLESS
Registry [2, 4••, 5••]. Together the latter represent data
on just over 800 patients who have been implanted with
the system with smaller series reported from Nether-
lands, UK & Germany (Table 1) [11•, 12, 13]. Since
the larger IDE & EFFORTLESS cohorts represent more
recent experience with adequate population numbers to
enable meaningful conclusions on system performance
to be drawn, the discussion will focus primarily on
these two large studies and refer to the smaller series
where appropriate.
Induced VF
The IDE trial was a prospective, non-randomised,
multicentre trial which studied adults with ICD standard
indications who neither required pacing nor documented
pace-terminable ventricular tachycardia [4••]. The prima-
ry effectiveness end point was the induced VF conver-
sion rate compared with a pre-specified performance
goal of 88 %. These successful shocks had to be two
consecutive VF conversions at 65J in either shock vec-
tor, within a maximum of four VF conversion attempts
with the use of the same polarity to qualify as a suc-
cessful DFT. An additional very stringent analysis was
performed in which patients in whom VF inductions
Fig. 1 a) The three shocking vectors that can be used by the device. b) Inappropriate T-wave oversensing in the primary and alternate vector during
exercise, with correction by use of the secondary vector
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could not be completed for technical or clinical reasons
were classified as failures, e.g. inability to induce VF or
the clinical status of the patient deemed by the
implanting physician made testing unsafe. The primary
effectiveness cohort consisted of 304 patients who com-
pleted the full testing protocol, providing evaluable con-
version tests according to the protocol definitions. The
conversion rate in these evaluable conversion tests dem-
onstrated 100 % acute conversion with a 95 % lower
confidence limit of 98.8 %, which exceeded the pre-
specified objective performance goal of ≥88 %. In a
total of 265 patients (82.8 %), acute conversion of VF
was successful on consecutive shocks one and two in
the first polarity tested after the final position was
achieved. Sixteen patients were deemed non-evaluable
and one patient who did not undergo any testing be-
cause of persistent left ventricular thrombus. Including
these 17 excluded patients as VF conversion failures
reduced the acute VF success conversion rate to
94.7 % with a 95 % lower confidence limit of
91.7 %, still exceeding the pre-specified performance
goal of 88 %. This data is very similar to that reported
in the initial analysis of EFFORTLESS which reported
on induction testing in 393 patients with complete data
[6••, 14]. Due to the variability in acute defibrillation
testing protocols in the latter at each clinical site, suc-
cessful conversion efficacy at implant was defined for
the Registry as at least one successful conversion of an
induced ventricular arrhythmia at ≤80J. In eight cases
information was incomplete, while in nine patients VT/
VF was not inducible. Of the 393 patients with com-
plete data, in all but one patient VT/VF was success-
fully converted (99.7 %). Seven of these patients had an
initial conversion failure that required one or more
procedures to reposition the system to become success-
ful. A shock energy of ≤65J was successful in 95 % of
patients. Therefore, the acute conversion rate was
similar and times to therapy were 15.1±3.8 s (range=
7.0-37.0 s) for 65J shocks versus 14.6±2.9 seconds,
(range 9.6- 29.7 s) in IDE.
Spontaneous VT/VF Episodes
The IDE study reported 119 spontaneous VT/VF episodes in
21 patients (38 discrete VT/VF episodes and 81 occurring
during VT/VF storms). The 38 discrete VT/VF episodes
consisted of 22 episodes of monomorphic VT (13 patients)
and 16 episodes of polymorphic VT or VF (11 patients) [4••].
A total of 43 appropriate shocks were delivered in these 38
discrete VT/VF episodes, all of which terminated the arrhyth-
mia. The S-ICD System converted 35 of 38 episodes (92.1 %)
on the first shock and 37 of 38 (97.4 %) with one or more
shocks. This compares to the EFFORTLESS data where 169
episodes received therapy in 59 patients. Of these, 93 episodes
(55 %) in 33 patients were classified as VT/VF; 51 were
discrete episodes (n=29 patients) and 40 were episodes re-
corded during VT/VF “storms” (defined as ≥3 treated VF/VT
episodes within 24 hrs) with two additional VT/VF episodes
which spontaneously converted prior to first shock. Of the 51
discrete episodes receiving therapy, 45 converted to sinus
rhythm either immediately or within a few seconds after the
first shock (type 2 break, n=3) giving a first shock conversion
efficacy of 88%. In the remaining six episodes, more than one
shock was required to achieve cardioversion to sinus rhythm.
The overall shock conversion efficacy per protocol definition
of successful conversion within one device-defined episode
and five shocks was 96 % (49/51 episodes). The mean time to
therapy was 17.5 (±4.4) seconds with a range of 6.0 to
29.4 seconds reflecting a slightly longer charge time for the
higher energy shock delivery in the ambulatory setting.
Six VT/VF storm events in four patients resulted in the 40
episodes in the EFFORTLESS cohort [6••]. One renal dialysis
patient had multiple VT/VF storm events over a period of
17 months post implant and subsequently died due to pump
Table 1 Main published S-ICD cohorts
Study population n Case mix Mean age Appropriate shock Inappropriate shock Complications Mean Cumulative
1° prevention (y) rate rate overall FUp/pt FUp
(%Pts) (%Pts) (%Pts)
Bardy et al. 1st
European Trial
55 78 % 56±13 5.5 % 10 months 46 pt-years
IDE 314 79.4 % 51.9±15.5 6.7 % 13.1 % 7.9 % at 180d 330d 289 pt-years
EFFORTLESS 472 63 % 49+18 7 % 7 % 6 % at 360d 558 d 721 pt-years
Dutch Cohort
Study
118 38 % 50+14 7 % 13 % 11.9 % 18 m 177 pt-years
German Initial
Cohort
40 42.5 % 42±15 10 % 5 % Nil 229 d 25 pt-years
UK Survey 111 33 (median) 12 % 15 % 1 arrhythmic death 12.7±7.1 months 117 pt-years
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failure. In one case of a patient with Loeffler’s syndrome, the
VF storm was preceded by a 10 minute period of bradycardia
(lowest heart rate of 28/min in the 60 seconds pre-arrest). The
VF that subsequently developed was not successfully
defibrillated, and the patient died. This unusual patient had
obliteration of the RV and LV apices by a mass and was not
deemed suitable for a standard ICD system. At implant VF
had been sensed appropriately and cardioverted at 65J.
Other studies have reported equivalent data (Table 1 [11•,
12, 13]), but with no other failures to cardiovert VF. An age and
sex matched study (n=69) comparing defibrillation efficacy in
S-ICD and transvenous ICD (TV-ICD) patients demonstrated a
first shock efficacy of induced VF of 89.5 % using a 15 J safety
margin compared to TV-ICD of 90.8 % (p=0.8) increasing to
95.5%with a second shock at reversed polarity [15]. In the UK
survey study, there was one arrhythmic death which was
thought to be due to a bradycardia. No other suspicious ar-
rhythmic deaths have been described. Therefore, in the total of
1110 patients implanted to date it appears there have been two
arrhythmic deaths with one due to failed conversion of VF in a
patient whom the pathological process of eosinophilic infiltra-
tion could have caused an elevation in DFT. Concerns have
been raised regarding the more prolonged detection and charge
times seen in a proportion of S-ICD patients versus standard
ICD systems. On average standard ICD times to detection and
shock therapy are approximately 5 seconds shorter [16]. How-
ever, as discussed later these delayed detection and charge
times may actually help reduce unnecessary shocks due to
self-termination of VT/VF and even be a factor in reducing
mortality in ICD recipients.
Inappropriate Shocks
Awell recognised issue in ICD function has been the problem
of inappropriate shocks which range in incidence from 12-17%
in randomised controlled trials [17••, 18••, 19, 20]. There have
been concerns that this will present a major hurdle to S-ICD
uptake since the device relies on surface ECG electrograms as
opposed to intracardiac signals for arrhythmia detection, mak-
ing it more susceptible to error from T wave oversensing and
electromagnetic interference (EMI) [9, 21, 22].
In the IDE trial, the incidence of inappropriate therapy was
13.1 % (41 patients) over the 11-month mean follow-up.
Supraventricular tachycardia in the high-rate zone (no dis-
criminators), in which rate alone determines whether a shock
is delivered, was the cause in 16 patients (5.1 %) [4••].
Oversensing causing inappropriate shocks occurred in 25
patients (8.0 %); 22 patients experienced oversensing of T
waves or, more rarely, broad QRS complexes, and in three
patients as a result of external noise due to EMI from electrical
equipment. Interestingly, as experience with dual zone pro-
gramming increased in the latter 2/3 of patients treated in the
trial, both T wave oversensing and SVT triggered inappropri-
ate shocks showed relative reductions in incidence of 56 %
and 70 % respectively. No patients suffered shocks due to
discrimination errors in the SVT zone.
In EFFORTLESS, experience has been similar with 73
inappropriate shocks recorded in 32 patients over an average
follow-up of 18 months (360 day inappropriate shock rate of
7 %). The majority of inappropriate shocks were due to
oversensing (85 %) most frequently of cardiac signals (94 %
of over-sensed episodes). In four patients, inappropriate
shocks were due to noise or EMI while six patients had
inappropriate therapy due to supraventricular arrhythmia
(SVT) rates that crossed into the shock-only zone. There
was one episode of discriminator error, in which morphology
was impacted by a clipped signal. Therefore, both studies
indicate that programming SVT zone (rate plus discrimina-
tors) significantly impacts on reducing inappropriate shocks
from the device.
Figure 2 shows the inappropriate shock rate of the IDE and
EFFORTLESS trials in comparison with transvenous ICD
Fig. 2 Inappropriate shocks, as a percentage of patients with ICD im-
planted in trials. AF-atrial fibrillation, SVT-supraventricular tachycardial,
ST-sinus tachycardia. mo. is months of follow up. MADIT II is Multi-
center Automatic Defibrillator Implantation Trial [19], IDE (S/C ICD) is
Subcutaneous ICD IDE study [4••], SCD-HeFT is Sudden Cardiac Death
in Heart Failure Trial [31•], DEFINITE is Defibrillators in Non- Ischemic
Cardiomyopathy Treatment Evaluation [20], ALTITUDE is ALTITUDE
Survival Study [30], Pittsburgh Study [33], EFFORTLESS [6••]
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trials. It can be seen that the percentage of patients experiencing
inappropriate shocks in the IDE trial is not dissimilar to expe-
riences with conventional ICD implantation. Abnormal sensing
was the major cause of inappropriate shocks in the IDE and
EFFORTLESS studies when compared to other trials, however
as experience has grown, the change to dual zone programming
and optimising of screening to minimise T wave oversensing,
will likely see a reduction in this number [9].
The device has been widely used beyond the standard
ischaemic and dilated cardiomyopathy populations including
patients with ion channel disorders (long QT syndrome,
Brugada syndrome, catecholaminergic polymorphic VT
(CPVT)), hypertrophic cardiomyopathy and congenital heart
disease [23–26]. Indeed in the EFFORTLESS registry a sig-
nificant proportion of cases had ion channel disorders and
idiopathic VF. These disease sub-populations represent a sig-
nificant challenge in terms of risks of Twave oversensing and
inappropriate shocks due to increased heart rates as there are
more frequent dynamic changes both in T wave and QRS
morphology in these patients [27]. Furthermore, being youn-
ger than standard ICD recipients, they often achieve higher
exercise heart rates which are at risk of putting them into a VF
therapy zone if this is programmed too low, e.g. 200 beats/
min. A number of these conditions especially CPVT cause
increased ventricular ectopy and bigeminy which can present
significant challenges to any ICD as rate and morphology
discriminators may well classify a bigeminal rhythm as VF
due to morphology changes and potentially T wave
oversensing of the ectopic beats. This was a particular issue
with the early experience in one group of young inherited
arrhythmia patients – consisting of 12 patients with primary
ventricular arrhythmic disorders: four long QT syndrome
(LQTS), three catecholaminergic polymorphic VT (CPVT),
three Brugada syndrome, two idiopathic VF and four cases
with structural congenital heart disease [27]. Four of these
patients experienced a total of ten inappropriate shocks, all
due to T-wave over-sensing. There were no significant differ-
ences between characteristics of patients with and without
inappropriate shocks. In two patients with CPVT, these oc-
curred during frequent polymorphic ventricular ectopy and
sinus tachycardia in an Ebstein’s and LQT patient. The medi-
an detection rate programmed at the time of the events was
220 bpm (range 190–220 bpm). In two cases a delay in VF
therapy occurred due to noise initially detected on the electro-
gram. Both patients were programmed with a single shock
zone from 220 bpm. One episode of VF was quite prolonged
before therapy (27 s); analysis revealed that the presence of a
conditional sock zone from 200 bpm would have reduced the
time to onset of charging from 14 to 9 s. This is because the
earlier events in the episode, prior to detection of tachycardia,
were sensed with a frequency between 200 and 220 bpm. The
presence of a zone from 200 bpmwould have therefore caused
these earlier events to be classified as tachycardia; however
this would increase the risk of T wave oversensing and inap-
propriate shocks in these cases. This small series highlights
the challenges in optimal patient selection for the S-ICD and
the need for careful ECG screening at rest and on exercise to
minimise the risk of inappropriate shocks in these young often
more vulnerable channelopathy patients. However, these is-
sues have not been raised as a major concern in the later
experience of larger Dutch series and EFFORTLESS chan-
nelopathy populations [11•].
Limitations of the S-ICD: Bradycardia Pacing
and Anti-Tachycardia Pacing (ATP)
The S-ICD system is unable to deliver permanent pacing or
ATP to terminate VT. It can deliver 30 s of transthoracic post-
shock pacing if the patient is severely bradycardic. Therefore,
it cannot be employed in patients with pacing indications. This
raises the question as to what proportion of patients who
would qualify for an S-ICD would ultimately require pacing
or ATP & hence need conversion of their device to a
transvenous system. A recent Dutch study of ICD recipients
reviewed 463 patients followed up over a median of 3.4 years
between 2002-11 [28]. It was demonstrated that 55.5 % (95 %
CI 52.0% to 59.0%) of single or dual chamber ICD recipients
would have been suitable for an initial S-ICD implantation
after 5 years, i.e. did not develop a pacing indication or receive
ATP from their device. Significant predictors for the unsuit-
ability of an S-ICD were: secondary prevention, severe heart
failure and prolonged QRS duration.
The risks and benefits of ATP to terminate VT have come
into sharp focus recently from the Reduction in Inappropriate
Therapy and Mortality through ICD Programming (MADIT-
RIT) study which randomised 1500 patients to three treatment
strategy arms: (i) A control group was programmed to treat
rates >170 beats per minute with a short delay after initial
detection and multiple ATP sequences in the lower rate zone
(ii) single zone of therapy at 200 beats per minute with
conventional detection delay and ATP while charging or (iii)
three-zone therapy arm with prolonged delays; both included
use of ATP. Both arms (ii) and (iii) were associated with a
significant reduction in appropriate and inappropriate ICD
therapy [29•]. In addition to more ICD shocks, there was a
significant three-five fold greater use of ATP in the conven-
tional programming control arm versus the comparator arms.
Importantly, the patients randomised to the single zone, high
rate programming strategy treating only high ventricular rates
had a significant reduction in all-cause mortality when com-
pared with those of the conventional arm. The simpler pro-
gramming strategy reflects the S-ICD programming platform
of high-rate zones of therapy and prolongation of the time
from detection to shock delivery, thereby minimising
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unnecessary ICD therapy [17••], however direct comparisons
cannot bemade as the S-ICD system does not have the capacity
to perform ATP pacing while charging. In the S-ICD IDE trial,
the time to therapy for appropriate shocks was 14.6±2.9 s
which is within the range of prolongation in detection shown
to be beneficial in MADIT-RIT. However, debate continues
regarding the risk versus benefits of prolonged detection facil-
itating self-termination of VT/VF episodes and potentially
reduced mortality from unnecessary ATP and shocks versus a
potentially higher risk of syncope or avoiding shocks through
pace termination of VT [16]. Of note however, in the ALTI-
TUDE Registry, there was a recognised increase in mortality
for patients receiving ATP accelerating VT (hazard ratio, 3.03;
95 % confidence interval, 2.65–3.46) [30].
A further point is the proportion of patients likely to devel-
op monomorphic VT that is pace-terminable. In the SCD-
HeFT ICD study of 811 patients, 182 (22 %) received at least
one ICD shock for VT or VF- 50 % (12 % of the 811) had at
least one episode of de novo VF which was not preceded by
any VT, while two-thirds of the 182 patients (15% of 811) had
one or more episodes of monomorphic VT (>188 bpm) [31•].
Therefore, it could be estimated that ≈15 % of patients with
moderate heart failure may experience high rate monomorphic
VT during the first few years following an ICD. Over
45.5 months of follow up, only 1/3 of the patients with VT
had more than a single episode in SCD-HeFT, representing
only 7 % of the 811 ICD patients in the trial, or a 1.8 % per
year risk which is less than the reported risk of transvenous
lead failure [17••].
Complications
The main complications of the S-ICD system have related to
infection and suboptimal lead position/movement. In IDE &
EFFORTLESS all complications were grouped as follows: all
device related (type I), labelling-related (type II), and proce-
dure related (type III). In IDE, the 180-day type I-III
complication-free rate was 92.1 % with a lower confidence
limit of 88.9 %, above the pre-specified performance goal
[4••, 5••]. In EFFORTLESS, 15 system related complications
in 14 patients (3 %) occurred in the first 30 days post implant,
which accounts for a peri-operative complication-free rate of
97 % [6••]. At 360 days post implant, the documented system
or implantation-related complication-free rate was 94 %.
Either suspected or confirmed infections were reported in
5.7 % of IDE patients and 4 % of EFFORTLESS, the majority
responding to antibiotics for superficial wound involvement.
However, 1.3 % of cases required explanation in IDE and
2.2% in EFFORTLESS. It is thought that the majority of these
infections may relate to initial inexperience with surgical
technique of implantation and certainly as physician experi-
ence grew and rigorous procedural attention to technique was
developed, infection requiring explanation declined in IDE.
This early experience of higher initial complication rates was
pointed out in the Dutch cohort which then demonstrated
significant reductions both in inappropriate shocks and device
related complications over time [11•]. Many of these were
correctable by optimising screening for T wave oversensing
on exercise, utilising a suture sleeve to prevent lead migration
and reductions in implant time reducing infection rates with
increased implanter experience and improvements in tech-
nique. Indeed a recent development by the Dutch group
avoids the 3rd superior incision to anchor the lead by simply
tunnelling the lead through a splittable sheath and anchoring it
inferiorly with the suture sleeve [7•]. Lead stability is main-
tained and the additional incision with extra infection risk and
its cosmetic impact avoided.
Conclusion and Future Directions
Early experiences highlight the S-ICD as a viable alternative
to conventional transvenous ICD implantation in patients who
do not have a requirement for pacing. Its major advantage is
that it negates the risks associated with transvenous lead
placement, avoiding acute and chronic lead complications.
This has genuine advantages in patients who are young, where
longevity of transvenous leads is a real concern. This technol-
ogy therefore has the potential to change and expand the use
of ICDs. Although initial trials show a comparable defibrilla-
tion success rate and similar rates of inappropriate therapy to
conventional systems, there will be improvements in the de-
vice’s surface analysis of heart rhythm; as has already oc-
curred in the lifespan of both the IDE [4••] and EFFORTLESS
[6••] studies; where the incidence of oversensing has been
reduced by dual zone programming. Further developments in
the device’s programming will no doubt refine rhythm dis-
crimination. A better understanding of its role in young pa-
tients with inherited arrhythmia disorders and cardiomyopa-
thies such as Brugada, long-QT and HCM, through larger
studies are needed along with the programming optimisations
that these patients may require.
There is a vital need to continue to monitor the device’s
long term performance, safety and efficacy. At present studies
have focussed on early experience. However, a randomised
controlled trial (The Netherlands-based Prospective, RAn-
domizEd comparison of subcuTaneOus and tRansvenous Im-
plANtable cardioverter-defibrillator therapy study
(PRAETORIAN) comparing subcutaneous ICD and trans-
venous ICD systems in suitably indicated patients is in prog-
ress and should allow contemporary comparison between the
systems on a number of levels [32]. Next generation S-ICD
systems will be reduced in volume to facilitate implantation in
thinner patients and paediatric cases. Wireless communication
will facilitate remote follow-up. There are also rapid
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developments occurring in the field with the deployment of
leadless electrodes (Nanostim) for pacing which will poten-
tially widen the indication for S-ICD patients to incorporate
patients requiring pacing provided oversensing challenges can
be overcome. Since paced patients have been successfully
implanted with the S-ICD these should be manageable.
Early work is therefore clearly positive in showing that this
device compares favourably with conventional ICD systems.
As further long term studies and improvements to the
device are made, the scope of the S-ICDs future role
will become clear.
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